Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 180 publications
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.
Journal: JCO oncology practice
Published: June 23, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 29, 2026
Correction: Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection.
Journal: Annals of surgical oncology
Published: April 24, 2026
First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study.
Journal: Journal for immunotherapy of cancer
Published: April 09, 2026
CLO26-116: Epigenetic Modulation Using Combined oral Decitabine/Cedazuridine (DEC-C) and Nivolumab in Unresectable or Metastatic Mucosal Melanoma: A Phase Ib/II Trial.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Neoadjuvant and adjuvant therapy in uveal melanoma: toward systemic control of a systemic disease.
Journal: Cancer treatment reviews
Published: March 04, 2026
Translating ctDNA into cutaneous melanoma care: An international expert survey.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 13, 2026
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.
Journal: Cancers
Published: November 27, 2025
Decitabine reverses innate immune gene suppression in rare melanomas.
Journal: Molecular cancer therapeutics
Published: November 04, 2025
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.
Journal: Cancer discovery
Published: October 07, 2025
Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
Journal: ESMO open
Published: September 24, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Journal: Cancer discovery
Published: September 17, 2025
Last Updated: 09/26/2026